NORTHWEST BIOTHERAPEUTICS INC (NWBO): M&A transaction — Northwest Biotherapeutics completes acquisition of UK CDMO Advent BioServices for ~$1.9M plus ~$8.3M payables

NORTHWEST BIOTHERAPEUTICS INC

Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.
Payment in installments over 2 years starting 3 months after close, with potential acceleration upon DCVax-L regulatory approval.
Related-party transaction: CEO Linda Powers controls seller; approved per company policies.
Company retired 12M shares and cancelled 5.5M stock options previously issued to Advent.
SEC granted waiver from providing Advent financial statements and pro forma info under Regulation S-X.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NORTHWEST BIOTHERAPEUTICS INC completed an acquisition involving Toucan Holdings LLC for purchase price of approximately $1.9 million (£1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for (closed 2025-10-24).

Action: acquisition
Counterparty: Toucan Holdings LLC
Consideration: purchase price of approximately $1.9 million (£1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for
Closing: 2025-10-24

Exact text from the filing

with potential acceleration after regulatory approval of the Company’s DCVax®-L product. The consideration for the acquisition consists of a purchase price of approximately $1.9 million (£1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for manufacturing and related services already provided under

View on SEC.gov

Browse all m&a transactions →

NORTHWEST BIOTHERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-26-040260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.